All In Biotech

Drug Trial Radar · NCT07497880

Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 306 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

306

Actual

Start

Apr 6, 2026

Primary completion

Jul 7, 2027

Study completion Jul 7, 2027

Sponsor

Lead sponsor
KaileraIndustry
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine the efficacy of oral KAI-7535 once daily compared with placebo on percent change in body weight in participants living with obesity or overweight, with at least 1 weight-related comorbidity, without diabetes mellitus. Safety and tolerability and other weight-related outcomes will also be evaluated.

Conditions

  • Obesity
  • Overweight

Interventions

  • KAI-7535Drug

    Oral tablets

  • PlaceboDrug

    Oral tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change from Baseline in Body Weight at Week 44 for Participants Without Diabetes MellitusTime frame: Baseline, Week 44

Locations

36 sites in 2 countries. Site status is shown where the registry gives one.

  • Kailera Clinical Site

    Chandler, Arizona

  • Kailera Clinical Site

    Phoenix, Arizona

  • Kailera Clinical Site

    Irvine, California

  • Kailera Clinical Site

    Lincoln, California

  • Kailera Clinical Site

    Northridge, California

  • Kailera Clinical Site

    Hamden, Connecticut

  • Kailera Clinical Site

    Jacksonville, Florida

  • Kailera Clinical Site

    Jupiter, Florida

  • Kailera Clinical Site

    Palm Springs, Florida

  • Kailera Clinical Site

    Pembroke Pines, Florida

  • Kailera Clinical Site

    Decatur, Georgia

  • Kailera Clinical Site

    Chicago, Illinois

  • Kailera Clinical Site

    Skokie, Illinois

  • Kailera Clinical Site

    South Bend, Indiana

  • Kailera Clinical Site

    Kenner, Louisiana

  • Kailera Clinical Site

    Garden City, Michigan

  • Kailera Clinical Site

    Jefferson City, Missouri

  • Kailera Clinical Site

    Kansas City, Missouri

  • Kailera Clinical Site

    Spartanburg, South Carolina

  • Kailera Clinical Site

    Knoxville, Tennessee

  • Kailera Clinical Site

    Austin, Texas

  • Kailera Clinical Site

    Austin, Texas

  • Kailera Clinical Site

    Brownsville, Texas

  • Kailera Clinical Site

    Farmers Branch, Texas

  • Kailera Clinical Site

    Fort Worth, Texas

  • Kailera Clinical Site

    Mesquite, Texas

  • Kailera Clinical Site

    San Antonio, Texas

  • Kailera Clinical Site

    San Antonio, Texas

  • Kailera Clinical Site

    San Antonio, Texas

  • Kailera Clinical Site

    Sugar Land, Texas

  • Kailera Clinical Site

    Sandy City, Utah

  • Kailera Clinical Site

    Dee Why, New South Wales, Australia

  • Kailera Clinical Site

    Miranda, New South Wales, Australia

  • Kailera Clinical Site

    Wollongong, New South Wales, Australia

  • Kailera Clinical Site

    Norwood, South Australia, Australia

  • Kailera Clinical Site

    Altona N., Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.